Vertex Pharma's most recent trend suggests a bearish bias. One trading opportunity on Vertex Pharma is a Bear Call Spread using a strike $72.50 short call and a strike $77.50 long call offers a potential 11.11% return on risk over the next 18 calendar days. Maximum profit would be generated if the Bear Call Spread were to expire worthless, which would occur if the stock were below $72.50 by expiration. The full premium credit of $0.50 would be kept by the premium seller. The risk of $4.50 would be incurred if the stock rose above the $77.50 long call strike price.
The 5-day moving average is moving up which suggests that the short-term momentum for Vertex Pharma is bullish and the probability of a rise in share price is higher if the stock starts trending.
The 20-day moving average is moving up which suggests that the medium-term momentum for Vertex Pharma is bullish.
The RSI indicator is below 20 which suggests that the stock is in oversold territory.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Vertex Pharma
Vertex Pharmaceuticals' Management Presents at 2013 Deutsche Bank BioFEST Conference (Transcript)
Tue, 03 Dec 2013 01:02:02 GMT
Seeking Alpha – Robyn Karnauskas – Deutsche Bank And thinking about one of the big events I want to focus on, the 809 combination study last year. Can you remind us the powering of that study? And I'm just curious, so …
Vertex: CF Drug Approval To Save The Company
Mon, 02 Dec 2013 18:49:47 GMT
Seeking Alpha – Innovation is the passport to the future growth in the biotechnology industry. As long as the companies in this industry are able to come up with blockbuster drugs and get them approved by the U.S. Food …
Obamacare Winner: The Not-So-Hidden Industry Poised to Profit
Sat, 30 Nov 2013 19:34:21 GMT
Motley Fool – Despite discounts on drugs, certain drugmakers look poised to benefit from increased enrollment in Obamacare.
Nasdaq Leads Stocks Higher; Archer Daniels Deal Blocked
Fri, 29 Nov 2013 17:25:00 GMT
Investor's Business Daily – Nasdaq Leads Stocks Higher; Archer Daniels Deal Blocked
Johnson & Johnson Wins Hep C Battle, but War Doesn't Look Good
Mon, 25 Nov 2013 18:36:05 GMT
Motley Fool – Johnson & Johnson beats Gilead Sciences to deliver the first next-generation hepatitis C drug approved in the U.S., but a battle with Vertex Pharmaceuticals' and Merck's first-generation drugs will be …
Related Posts
Also on Market Tamer…
Follow Us on Facebook